Opinion|Videos|January 12, 2024
Strategies for Managing Treatment-Naïve CLL with High-Risk Features
Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.
Advertisement
Episodes in this series
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
3
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5